logo
Food dyes: Removing them doesn't make products healthy

Food dyes: Removing them doesn't make products healthy

CNN26-06-2025
In the crusade to reduce chronic disease and neurobehavioral issues in the United States, synthetic food dyes are a hot target.
California began paving the way for legislation against petroleum-based synthetic dyes a few years ago, based on health concerns including a potentially increased risk of cancer and neurobehavioral issues in children and animals. Gov. Gavin Newsom banned red dye No. 3 in 2023 and six other common dyes from school foods in 2024. Since then, 25 other states have followed in California's footsteps with legislation — some signed into law, others still in progress — that would either ban, restrict or require labels for food dyes.
Some state legislators were inspired by the scrutinization of artificial food dyes by the 'Make America Healthy Again' movement launched by US Health and Human Services Secretary Robert F. Kennedy Jr. The US Food and Drug Administration announced in April its plans to work with industry to phase out the use of petroleum-based synthetic dyes in the food supply.
But experts find it important for policymakers and the public to remember that dyes are just one component of highly engineered ultraprocessed foods. Accordingly, 'removing synthetic food dyes does not automatically transform the products into healthy foods or beverages,' said Dr. Jennifer Pomeranz, associate professor of public health policy and management at the New York University School of Global Public Health, via email.
A new study helps quantify Pomeranz's sentiment, finding that foods and beverages with synthetic dyes contained 141% more total sugar on average compared with products without synthetic dyes. Sodium and saturated fat, however, were lower in foods with dyes, according to the study published Wednesday in the Journal of the Academy of Nutrition and Dietetics.
The results indicate that synthetic food dyes can be considered a 'red flag' for a product that is likely less healthy overall, said Dr. David Andrews, acting chief science officer at the Environmental Working Group, a nonprofit health and environmental advocacy organization, via email. Andrews was not involved in the study.
Like many lawmakers legislating against food dyes, lead study author Dr. Elizabeth Dunford's pursuit of this research was driven by both 'a personal and professional curiosity,' she said via email.
'I am a mom of two young kids — aged 7 and 5 — and definitely notice behavioral changes, in my son in particular, after eating or drinking sugary products colored with synthetic dyes,' said Dunford, a consultant for The George Institute for Global Health's food policy division. 'But also my main professional research area is examining the healthiness of food supplies, with a specific interest in nutrient profiling and the use of food additives.'
Ultraprocessed foods, or UPF, comprise up to 70% of the US food supply and are made with industrial techniques and ingredients 'never or rarely used in kitchens,' according to the Food and Agriculture Organization of the United Nations. These foods are typically low in fiber and high in calories, added sugar, refined grains and fats, sodium, and additives, all of which are designed to help make food more appealing.
Additives often include preservatives to maintain freshness and texture or resist mold and bacteria, and emulsifiers to prevent ingredients from naturally separating. Other common additives include fragrance and flavor enhancers and agents for anti-foaming, bleaching, bulking, gelling and glazing.
Numerous studies published over the past several decades have linked consumption of ultraprocessed foods to diseases or health issues including type 2 diabetes, cardiovascular disease, obesity, premature death, cancer, depression, cognitive decline, stroke and sleep disorders. And the risks for some of these problems begin at just one daily serving of ultraprocessed foods, according to multiple studies. This evidence is why some of the states with laws or bills restricting food dyes have included popular additives, such as brominated vegetable oil or propylparaben.
It's also why experts caution against eating such foods even if they're colored with natural dyes, which industry is shifting toward amid federal and state pressure. Texas Gov. Greg Abbott signed into law on Sunday first-of-its-kind legislation that requires labels on foods or beverages containing 44 dyes or additives.
Additionally, the Kraft Heinz Company will phase out synthetic dyes from the roughly 10% of its US portfolio that still contains them before the end of 2027, the company told CNN Wednesday.
'The percentage of products with synthetic dyes is much lower than the percentage of products that are UPF, thus natural colors enabling the overeating of UPF are a problem,' Dr. Jerold Mande, CEO of Nourish Science, a nongovernmental organization focused on nutrition crises in the US, said via email. Mande wasn't involved in the study.
The primary focus of the new study led by Dunford was measuring the use of synthetic dyes in 39,763 food and beverage products sold by the top 25 manufacturers in the US, using 2020 data from Label Insight, a NielsenIQ company for product insights.
Up to 19%, or 1 in 5, of the products contained anywhere between one and seven synthetic dyes, the researchers found. The most used artificial dye was red dye No. 40, followed by red dye No. 3 and blue dye No. 1.
The food categories with the highest usage of dyes were sports drinks (79%), beverage concentrates (71%) and confectionery (54%). 'Carbonated beverages represented the largest proportion of total sales of products containing synthetic dyes (30%), due to it being the highest- selling category,' the authors wrote.
But some manufacturers have pointed out that changes in the marketplace since 2020 may impact the current percentages. Still, dyes are still a significant part of the food system, and many of these products remain on the market.
To some extent, the study is likely still 'a good picture of the landscape since it typically takes 18 months for big companies to change their supply chain to enable reformulation,' said Mande, who is also an adjunct professor of nutrition at the Harvard T.H. Chan School of Public Health.
The research also provides baseline information for change in light of the national spotlight on removing certain colorants from the food supply, especially from schools, said Pomeranz, who was not involved in the study.
'It is critical that regulatory agencies continue to prioritize research that is peer reviewed and relevant to health and human safety,' Sarah Gallo, senior vice president of product policy at the Consumer Brands Association, said via email. 'The makers of America's household brands are constantly innovating to meet consumer demand and offer a number of product options with natural ingredients in the marketplace.' The association represents the food industry.
'Additionally, the industry has invested in consumer transparency tools such as SmartLabel and Facts up Front so that families can review product ingredients and nutrition information and make decisions best for them,' Gallo added.
People concerned about food dyes and ultraprocessed foods should move toward whole foods and unsweetened drinks and away from ultraprocessed foods and beverages, as much as they can afford to given high costs, Pomeranz said.
Increase your intake of whole fruits, veggies, grains, nuts and seeds, and legumes. You should also be aware of how much sodium you're eating and how certain foods make you feel — ultraprocessed foods can keep you wanting more, while whole foods are more satiating.
Read ingredient labels when you shop, experts said. 'One thing that did surprise me was the presence of synthetic dyes in products I was not expecting them — such as plain hot dog buns, taco shells, bagels, waffles etc.,' said Dunford, adjunct assistant professor in the department of nutrition at the University of North Carolina at Chapel Hill.
Some experts have argued that to truly improve the nation's health, there also needs to be a larger focus on making healthy foods more accessible.
However, the MAHA movement 'has made big-food-caused chronic disease a political priority. That's a policy game-changer,' Mande said. 'Focusing on colors is a reasonable first step to disrupting the ultra-formulation food business model.'
But 'MAHA will need to take on ultra-formulations more directly, for example, limiting them in school meals, to succeed in improving child health,' he added.
EDITOR'S NOTE: Sign up for CNN's Eat, But Better: Mediterranean Style. Our eight-part guide shows you a delicious expert-backed eating lifestyle that will boost your health for life.
CNN's Sandee LaMotte contributed to this story.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Life Molecular Imaging Expands Neuraceq® (florbetaben F-18 injection) Production in Southern California
Life Molecular Imaging Expands Neuraceq® (florbetaben F-18 injection) Production in Southern California

Yahoo

time16 minutes ago

  • Yahoo

Life Molecular Imaging Expands Neuraceq® (florbetaben F-18 injection) Production in Southern California

Unlocking a new geography, making Neuraceq® available to more patients BOSTON, Aug. 20, 2025 /PRNewswire/ -- Life Molecular Imaging (LMI), a Lantheus company, dedicated to developing and offering novel PET radiopharmaceuticals, has expanded its manufacturing and distribution network for Neuraceq® (florbetaben F-18 injection) in Southern California. This expansion increases access to the broader Southern California area, including San Diego, extending availability of Neuraceq® to imaging centers, physicians, and patients with cognitive impairment. The first dose from a newly-equipped site in Los Angeles was provided on August 13, 2025. Neuraceq® is an FDA-approved radioactive diagnostic agent for the detection of amyloid plaques in the brain of adult patients with cognitive impairment who are being evaluated for Alzheimer's disease and other causes of cognitive decline. Neuraceq® is used in clinical routine and is also a powerful diagnostic tool for the appropriate characterization of patients assessed for treatment eligibility with newly approved anti-amyloid drugs. This expansion reflects LMI's ongoing commitment to advancing diagnostic access and improving outcomes for patients affected by Alzheimer's disease in California. "At LMI, we are focused on expanding geographical access to Neuraceq® for patients and physicians involved in the evaluation of Alzheimer's disease. As the adoption of anti-amyloid therapies continues to grow, the demand for reliable amyloid PET imaging is increasing in parallel. Launching Neuraceq® from Los Angeles is a key milestone in meeting this rising demand. It reflects our ongoing dedication to delivering timely, high-quality diagnostic solutions that align with the evolving needs of neurologists and patients," said Colleen Ruby, US Country Head and Chief Operating Officer, Americas and APAC of LMI, a Lantheus company. About Neuraceq® (florbetaben 18F) Indications and Use NEURACEQ is a radioactive diagnostic drug indicated for positron emission tomography (PET) of the brain to estimate amyloid beta neuritic plaque density in adults with cognitive impairment for: Evaluation of Alzheimer's disease (AD) and other causes of cognitive decline, and selection of patients who are indicated for amyloid beta-directed therapy as described in the prescribing information of the therapeutic products. CONTRAINDICATIONS: None WARNINGS AND PRECAUTIONS: Risk for Image Misinterpretation and other Errors: NEURACEQ Risk of Image Misinterpretation and Other Errors: Image interpretation errors have been observed. [see Section 5.1 of the full prescribing information] Radiation Risk: NEURACEQ, similar to other radiopharmaceuticals, contributes to a patient's overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk of cancer. Ensure safe handling to protect patients and health care workers from unintentional radiation exposure [see Dosage and Administration in the full prescribing information]. ADVERSE REACTIONS: The most commonly reported adverse reactions in clinical trials were injection site pain (3.4%), injection/application site erythema (1.7%), and injection site irritation (1.1%). For more information please visit: About Life Molecular Imaging (LMI) Life Molecular Imaging (LMI), a Lantheus company, is dedicated to developing and offering novel cutting-edge PET radiopharmaceuticals for imaging of neurodegenerative and cardiovascular diseases. The organization strives to be a leader in the molecular imaging field. Our mission is to pioneer innovative PET products that improve early detection and characterization of chronic and life-threatening diseases, leading to better therapeutic outcomes and improved quality of life. By advancing novel PET radiopharmaceuticals for molecular imaging, LMI is focusing on a key field of modern medicine. To learn more about LMI, please visit About LantheusLantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in New Jersey, Canada, Germany, Switzerland and Sweden, Lantheus has been providing radiopharmaceutical solutions for nearly 70 years. For more information, visit ContactsInvestor Relations: Mark KinarneyVice President, Investor Relations978-671-8842ir@ Media: Melissa DownsExecutive Director, External Communications646-975-2533media@ View original content to download multimedia: SOURCE Life Molecular Imaging

KROMATID Announces Successful Close of $8 Million Series C Funding Round, Exceeding Growth Capital Goals
KROMATID Announces Successful Close of $8 Million Series C Funding Round, Exceeding Growth Capital Goals

Yahoo

time16 minutes ago

  • Yahoo

KROMATID Announces Successful Close of $8 Million Series C Funding Round, Exceeding Growth Capital Goals

Funding positions KROMATID for accelerated growth in genomic analysis and gene editing technologies BOULDER, Colo., Aug. 20, 2025 /PRNewswire/ -- KROMATID, a leader in next-generation genomic structural analysis, today announced the successful close of its Series C funding round, raising a total of $8 million and surpassing its targeted capital goals. The most recent tranche of the round contributed $3.8 million. The round was led by BroadOak Capital Partners, with participation from both existing and new strategic investors. The capital from this Series C close will fuel expansion of KROMATID's proprietary platforms for detecting chromosomal structural rearrangements, scale operations to meet growing global demand, and advance strategic partnerships with pharmaceutical and academic leaders in cell and gene therapy. "We are thrilled to have achieved our funding goal, which is a testament to the confidence our investors have in our vision and the unique capabilities of our technology," said Jim Chomas, CEO of KROMATID. "This investment enables us to scale faster, innovate further, and continue delivering the genomic insights that help bring life-changing therapies to patients." "KROMATID has built a differentiated platform that provides accurate, high-resolution analysis of genomic integrity, one of the most pressing needs in the rapidly expanding gene and cell therapy industry," said Bill Snider, Partner at BroadOak Capital Partners. "We are proud to continue our partnership as they enter their next phase of growth." Over the next 12–18 months, KROMATID plans to deploy this funding to accelerate commercial expansion and enhance automation and throughput in its laboratory operations. The company will also invest in strategic hiring across scientific, operational, and customer-facing teams to meet increasing market demand and solidify its leadership position in genomic structural analysis. About KROMATIDKROMATID delivers next-generation genomic structural analysis solutions for gene and cell therapy developers, enabling precise detection of chromosomal structural rearrangements with unmatched clarity and resolution. By combining proprietary imaging and bioinformatics capabilities, KROMATID supports therapeutic innovation from discovery through regulatory approval. About BroadOak Capital PartnersBroadOak Capital Partners is a boutique financial institution that provides direct investment and investment banking services to companies in the life science tools, diagnostics, and biopharma services sectors. BroadOak has invested in more than 70 life sciences companies including over 35 exits. For more information, visit Media Contact:Amanda LadasGlobal Marketing ManagerKROMATIDaladas@ View original content to download multimedia: SOURCE KROMATID Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Pediatricians' association recommends COVID-19 vaccines for toddlers and some older children, breaking with CDC guidance
Pediatricians' association recommends COVID-19 vaccines for toddlers and some older children, breaking with CDC guidance

Yahoo

time16 minutes ago

  • Yahoo

Pediatricians' association recommends COVID-19 vaccines for toddlers and some older children, breaking with CDC guidance

For 30 years, vaccine recommendations from the Centers for Disease Control and Prevention have aligned closely with those from the American Academy of Pediatrics, or AAP. But on Aug. 19, 2025, the AAP published new vaccine recommendations that diverge from those of the CDC. The pediatrician association's move comes on the heels of unprecedented changes made earlier this year by Robert F. Kennedy Jr., as head of the Department of Health and Human Services, in how the government approves and issues guidance on vaccines. The biggest difference is in the AAP's guidance around COVID-19 vaccines for children. This new guidance comes as COVID-19 cases are once again rising across the U.S. and many parents and providers are confused by unclear guidance from federal health authorities about whether children should be vaccinated. In a Q&A with The Conversation U.S., David Higgins, a pediatrician, preventive medicine physician and vaccine delivery researcher from the University of Colorado Anschutz Medical Campus, explains the new guidance and what it means for parents. Higgins is also a member of the American Academy of Pediatrics. What are the AAP's new vaccine recommendations? The AAP recommends that all children 6 to 23 months old receive a complete COVID-19 vaccine series, consistent with recommendations for this age group in previous years. For children and adolescents ages 2 to 18, the AAP now advises a single dose if they are at higher risk, a change from previous years, when vaccination was recommended for all in this age group. Children at higher risk include those who have certain chronic medical conditions, who live in long-term care or group settings, who have never been vaccinated, or who live with family members at high risk. The AAP also recommends that COVID-19 vaccines remain available for any child or adolescent whose parent wants them to be protected, regardless of risk status. In all cases, the most updated version of the vaccine should be used. How do these recommendations differ from CDC guidance? The difference is substantial. The CDC currently advises what it calls 'shared clinical decision-making' for children ages 6 months to 17 years who are not moderately or severely immunocompromised. This means the decision is left up to individual discussions between families and their health care providers, but the vaccine is not treated as a routine recommendation. These current guidelines were made after Kennedy bypassed the agency's normal independent review process. That framework can be confusing for families and difficult for providers to implement. By contrast, the AAP recommendations identify the ages and conditions where the risk is highest while also supporting vaccine availability for any families who want it. Why are they diverging? The AAP has been publishing vaccine guidance since the 1930s, long before the CDC or the Advisory Committee on Immunization Practices, an independent panel of experts that advises the CDC, existed. Since 1995, the two groups have generally issued essentially identical vaccine guidance. But this year, the federal government dismissed the advisory committee's panel of independent scientists and immunization experts, raising questions about the credibility of CDC guidance. At the same time, misinformation about vaccines continues to spread. In response, the AAP decided to publish independent recommendations based on its own review of the latest evidence. That review showed that although the risks for healthy older children have declined compared with the early years of the pandemic, young children and those with specific conditions remain especially vulnerable. Additionally, a review of evidence by an independent expert group called the Vaccine Integrity Project, also released on Aug. 19, 2025, confirmed that there are no new safety concerns and no decline in the effectiveness of COVID-19 vaccines. COVID-19 continues to cause hospitalizations and deaths in children and remains a leading cause of serious respiratory illness. Will parents be able to follow these recommendations? This is still unclear. The AAP recommendations do not automatically guarantee insurance coverage. By law, insurance plans and the federal Vaccines for Children program, which provides vaccines for eligible children who might not otherwise be vaccinated due to cost or lack of insurance, are tied to Advisory Committee on Immunization Practices recommendations. Unless insurers and policymakers act to align with the AAP recommendations, there is a risk that parents would be forced to pay the costs out of pocket. Vaccine supply may also be an issue. Currently, only two COVID-19 vaccines are available for children under 12. Moderna's vaccine is approved only for children with at least one high-risk condition, while Pfizer's authorization for younger children may not be renewed. If that happens, any remaining Pfizer doses for this age group may be unusable, leaving a shortfall in available vaccines for children. Finally, implementation may differ depending on the type of provider. Some vaccine providers, such as pharmacists, operate under policies tied strictly to CDC recommendations, which may make it harder to follow AAP's schedule unless rules are updated. What happens next? Parents and providers are likely to face continued confusion, just as COVID-19 cases rise as children return to school. Much will depend on whether the Advisory Committee on Immunization Practices updates its own recommendations at its upcoming meeting, expected in September, and whether pediatric COVID-19 vaccines remain available. Until then, parents can speak with their pediatricians to understand the best protection for their children. This article is republished from The Conversation, a nonprofit, independent news organization bringing you facts and trustworthy analysis to help you make sense of our complex world. It was written by: David Higgins, University of Colorado Anschutz Medical Campus Read more: COVID-19 vaccines for kids are mired in uncertainty amid conflicting federal guidance RFK Jr. says annual COVID-19 shots no longer advised for healthy children and pregnant women – a public health expert explains the new guidance RFK Jr's shakeup of vaccine advisory committee raises worries about scientific integrity of health recommendations David Higgins volunteers as Vice President of the Colorado Chapter of the American Academy of Pediatrics and as a board member of Immunize Colorado. He was not involved in the development or publication of the American Academy of Pediatrics' immunization guidelines. The views and opinions expressed in this article are solely his own and do not represent those of the American Academy of Pediatrics. Solve the daily Crossword

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store